Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price traded down 22.9% during mid-day trading on Friday . The company traded as low as C$0.18 and last traded at C$0.19. 504,239 shares were traded during trading, a decline of 5% from the average session volume of 530,580 shares. The stock had previously closed at C$0.24.
Hemostemix Price Performance
The stock’s 50 day simple moving average is C$0.19 and its 200-day simple moving average is C$0.11. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The company has a market capitalization of C$26.96 million, a PE ratio of -5.39 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
- What Makes a Stock a Good Dividend Stock?
- Cisco Roars Back: Is the Tech Giant Reborn?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Albemarle’s Earnings Are In—Is the Stock a Buy Now?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
